Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
HNC-664 by Guangzhou Henovcom Bioscience for Idiopathic Pulmonary Fibrosis: Likelihood of Approval
HNC-664 is under clinical development by Guangzhou Henovcom Bioscience and currently in Phase I for Idiopathic Pulmonary Fibrosis. According to...